Literature DB >> 29796239

Time to reappraise the therapeutic place of celecoxib.

Ian L P Beales1.   

Abstract

Entities:  

Year:  2018        PMID: 29796239      PMCID: PMC5956647          DOI: 10.1177/2040622317749394

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


× No keyword cloud information.
  21 in total

Review 1.  Role of cyclooxygenase isoforms in gastric mucosal defence.

Authors:  B M Peskar
Journal:  J Physiol Paris       Date:  2001 Jan-Dec

2.  Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors.

Authors:  Hershel Jick; James A Kaye; Stefan Russmann; Susan S Jick
Journal:  Pharmacotherapy       Date:  2006-10       Impact factor: 4.705

3.  Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.

Authors:  N S Abraham; H B El-Serag; C Hartman; P Richardson; A Deswal
Journal:  Aliment Pharmacol Ther       Date:  2007-04-15       Impact factor: 8.171

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.

Authors:  Francis K L Chan; Jessica Y L Ching; Yee Kit Tse; Kelvin Lam; Grace L H Wong; Siew C Ng; Vivian Lee; Kim W L Au; Pui Kuan Cheong; Bing Y Suen; Heyson Chan; Ka Man Kee; Angeline Lo; Vincent W S Wong; Justin C Y Wu; Moe H Kyaw
Journal:  Lancet       Date:  2017-04-11       Impact factor: 79.321

6.  Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Authors:  Francis K L Chan; Angel Lanas; James Scheiman; Manuela F Berger; Ha Nguyen; Jay L Goldstein
Journal:  Lancet       Date:  2010-06-16       Impact factor: 79.321

7.  Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

Authors:  Francis K L Chan; Lawrence C T Hung; Bing Y Suen; Vincent W S Wong; Aric J Hui; Justin C Y Wu; Wai K Leung; Yuk T Lee; Ka F To; S C Sydney Chung; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

8.  Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

Authors:  Francis Ka Leung Chan; Vincent Wai Sun Wong; Bing Yee Suen; Justin Che Yuen Wu; Jessica Yuet Ling Ching; Lawrence Cheung Tsui Hung; Aric Josun Hui; Vincent King Sun Leung; Vivian Wing Yan Lee; Larry Hin Lai; Grace Lai Hung Wong; Dorothy Kai Lai Chow; Ka Fa To; Wai Keung Leung; Philip Wai Yan Chiu; Yuk Tong Lee; James Yun Wong Lau; Henry Lik Yuen Chan; Enders Kwok Wai Ng; Joseph Jao Yiu Sung
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

9.  Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system.

Authors:  Nicholas S Kirkby; Martina H Lundberg; Louise S Harrington; Philip D M Leadbeater; Ginger L Milne; Claire M F Potter; Malak Al-Yamani; Oladipupo Adeyemi; Timothy D Warner; Jane A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

Review 10.  Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.

Authors:  Michèle Bally; Nandini Dendukuri; Benjamin Rich; Lyne Nadeau; Arja Helin-Salmivaara; Edeltraut Garbe; James M Brophy
Journal:  BMJ       Date:  2017-05-09
View more
  2 in total

1.  Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.

Authors:  Ramanpreet Kaur; Dhimant Desai; Shantu Amin; Kaisar Raza; Aman Bhalla; Pooja Yadav; Naveen Kaushal
Journal:  Mol Cell Biochem       Date:  2022-08-24       Impact factor: 3.842

2.  Efficacy of an opioid-sparing analgesic protocol in pain control after less invasive cranial neurosurgery.

Authors:  Shahjehan Ahmad; Ryan Khanna; Alvin Chidozie Onyewuenyi; Nicholas Panos; Rory Breslin; Sepehr Sani
Journal:  Pain Rep       Date:  2021-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.